New drug combo targets 'Undruggable' lung cancer mutation
NCT ID NCT07294261
Summary
This study aims to test the effectiveness and safety of a new drug combination called goselasib for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have not yet received treatment for their advanced disease. It will enroll about 69 adults to see how well the combination shrinks tumors and controls the cancer. The main goal is to measure the overall response rate, which is the percentage of people whose tumors significantly shrink.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCAL ADVANCED OR METASTATIC NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University
Guangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.